Depression and SSRI Treatment During Pregnancy—Prioritizing Maternal Mental Health

Meaningful advances in the treatment of perinatal MDD require coordinated attention to multiple aspects of clinical care delivery and research, informed by a perspective accounting for the health needs of 2 generations. Expanding access to care—particularly in maternity, child health, and psychiatric care deserts—is a public health imperative. A structured decision-making process facilitates the provision of balanced information on the potential maternal and fetal risks of untreated or undertreated illness, the benefits of treatment, and the risks associated with SSRI exposure.

Corresponding Author: Katherine L. Wisner, MD, MS, Developing Brain Institute, Children’s National Hospital, 111 Michigan Ave NW, Washington, DC 20010 (KWisner@childrensnational.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.